BRNS

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies aimed at treating immunology and inflammatory diseases. The company specializes in guiding T cells to overcome autoimmunity and inflammatory conditions. Its product pipeline includes therapies such as VTP-200 for human papillomavirus-related cervical lesions and VTP-300 for chronic Hepatitis B, both of which have shown promising results in clinical trials. Barinthus operates primarily in the biopharmaceutical sector, targeting healthcare providers and patients in need of advanced immunotherapy solutions.